ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

palbociclib

Also written as “Palbociclib”, “PD-0332991” and “Palbociclib 125mg”.

Its studies are mostly in Breast Neoplasms · Carcinoma, Renal Cell · Sarcoma, Ewing · Squamous Cell Carcinoma of Head and Neck · COVID-19, led by 7 companies.

Drug pagePalbociclib: every studyMany companies study it; this page follows only the 35 they lead. All 225 studies, academic ones too, with its approvals and label.
Furthest: phase 4, since Jan 22, 201635 company-led studies, 4 open or runningNext primary completion: Dec 22, 2026 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Pfizerits history only291 open or runningphase 4since Jan 22, 2016Aug 30, 2005Dec 31, 2029phase 2 · NCT05226871
biotx.aiits history only10 open or runningphase 2since Apr 26, 2022Apr 26, 2022none ahead
Criteriumits history only11 open or runningphase 2since Sep 3, 2020Sep 3, 2020Dec 31, 2027phase 2 · NCT04567420
CSPC Pharmaceutical Groupits history only11 open or runningphase 1since Apr 16, 2025Apr 16, 2025Oct 2027phase 1 · NCT06941142
iOMEDICO10 open or runningphase 2since Aug 25, 2016Aug 25, 2016none ahead
Megalabsits history only10 open or runningphase 4since Mar 19, 2024Mar 19, 2024none ahead
Merckits history only11 open or runningphase 2since Jul 18, 2022Jul 18, 2022Dec 22, 2026phase 2 · NCT05468697

Also a collaborator on its studies: AstraZeneca and Bristol-Myers Squibb.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of iOMEDICO only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Aug 25, 2016First study: phase 2 study in Breast NeoplasmsFirst studyNCT02894398 · 388 enrolled · Germany

TargetBeta

“CDK6/cyclin D1 inhibitor; Cyclin-dependent kinase 4/cyclin D1 inhibitor”ChEMBL 37, by rule

Studies

The one study iOMEDICO leads. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT02894398Breast Neoplasms · Germany2CompletedFeb 15, 2023388

How it is read

Names in the registry

  • “Palbociclib”, 16 entries
  • “PD-0332991”, 12 entries
  • “palbociclib”, 5 entries
  • “Palbociclib 125mg”, 3 entries
  • “Palbociclib alone”, 3 entries

Codes read as this program: PD0332991.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.